Home Transmembrane Transporters -Immunology & Inflammation CD markers

CD markers

Isoform-selective Products

CD markers Products

  • All (213)
  • CD markers Inhibitors (18)
  • CD markers Antibodies (189)
  • CD markers Antagonists (3)
  • CD markers Agonist (1)
  • New CD markers Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
J Virol, 2020, 10.1128/JVI.00148-20
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Cell Rep Med, 2024, 5(2):101400
Cell Rep Med, 2023, S2666-3791(23)00310-5
Cell Rep Med, 2023, 4(9):101157
A2837 Anti-CD83 Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD.
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Cancer Immunol Immunother, 2024, 73(6):108
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S6239 PMX-53 PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
Thromb J, 2022, 20(1):24
A2027 Daratumumab (anti-CD38) Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.
Leuk Res, 2024, 147:107599
Brain Behav Immun Health, 2024, 42:100865
J Exp Med, 2022, 219(9)e20220214
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
J Extracell Vesicles, 2021, 10(5):e12078
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
A2029 Relatlimab (anti-LAG-3) Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells.
Mol Ther Nucleic Acids, 2024, 35(2):102225
Sci Rep, 2024, 14(1):31504
J Clin Invest, 2023, 133(9)e164528
S0474 Avacopan Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.
Nat Commun, 2024, 15(1):6519
Cell Death Dis, 2022, 13(5):500
A2372 Apamistamab (Anti-PTPRC / CD45) Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD.
A2815 Dalotuzumab (Anti-IGF1R / CD221) Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD.
A2373 Neihulizumab (Anti-PSGL1 / CD162) Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD.
A2816 Visilizumab (Anti-CD3) Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD.
A2817 Anti-CD34 Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD.
A2818 Felzartamab (Anti-CD38) Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD.
A2819 Mezagitamab (Anti-CD38) Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD.
A2820 Tregalizumab (Anti-CD4) Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD.
A2821 Anti-CD4 (TRX1) Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD.
A2823 Divozilimab (Anti-CD20) Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD.
A2824 Letaplimab (Anti-CD47) Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD.
A2825 Ligufalimab (Anti-CD47) Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD.
A2827 Urabrelimab (Anti-CD47) Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD.
A2830 Gatralimab (Anti-CD52) Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD.
A2388 Mupadolimab (Anti-NT5E / CD73) Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD.
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD.
A2168New Anti-human CD3 (UCHT1)-InVivo Anti-human CD3 (UCHT1)-InVivo reacts with human CD3ε a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily
A2390 Tesnatilimab (Anti-NKG2D / CD314) Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD.
A2143 Anti-mouse 4-1BB (CD137)-InVivo Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137.
A2834 Grisnilimab (Anti-CD7) Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD.
A2393 Lorvotuzumab (Anti-NCAM1 / CD56) Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD.
A2836 Iladatuzumab (Anti-CD79b) Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD.
A2147 Anti-mouse CXCR3 (CD183)-InVivo Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC).
A2395 Imaprelimab (Anti-MUC18 / MCAM / CD146) Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD.
A2838 Anti-CD9 Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD.
A2839 Anti-CDH1 / E-cadherin / CD324 Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD.
A2149 Anti-mouse CD19-InVivo Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily.
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
A2151 Anti-mouse IL-10R (CD210)-InVivo Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages.
S0525 ADH-503 (GB1275) ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
P1208New PMX 205 acetate

PMX 205 acetate is a cyclic hexapeptide that acts as a potent C5a receptor (C5aR, CD88) antagonist with an IC50 of 31 nM.
Ecotoxicol Environ Saf, 2025, 289:117627
Int Immunopharmacol, 2023, 125(Pt B):111112
A2402 Anti-Melanotransferrin / CD228 Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD.
A2154 Anti-mouse CD86 (B7-2)-InVivo Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member.
A2846 Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD.
A2852 Anti-CSF1R / M-CSFR / CD115 (LY3022855) Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD.
A2411 Polzastobart (Anti-LILRB2 / ILT4 / CD85d) Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities.
A2413 Mibavademab (Anti-LEPR / CD295) Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD.
A2414 Anti-LAMP1 / CD107a Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD.
A2159 Anti-mouse CSF1R (CD115)-InVivo Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family.
Cell Metab, 2024, S1550-4131(24)00415-7
A2127 Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro.
A2604 Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD.
A2130 Anti-mouse LFA-1α (CD11a)-InVivo Anti-mouse LFA-1α (CD11a)-InVivo(clone M17/4) is a monoclonal antibody reacts with mouse LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. It plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), and also functions in lymphocyte costimulatory signaling.
A2021 Tremelimumab (anti-CTLA-4) Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.
A2418 Lacutamab (Anti-KIR3DL2 / CD158k) Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD.
A2023 Obinutuzumab (anti-CD20) Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
A2133 Anti-mouse LAG-3-InVivo Anti-mouse LAG-3-InVivo (Clone: C9B7W) monoclonal antibody reacts with mouse LAG-3 also known as CD223. LAG-3 promotes immune responses by activating antigen-presenting cells. The C9B7W antibody has been reported to block the function of murine LAG-3 in vivo and in vitro.
A2421 Efalizumab (Anti-Integrin aL / ITGAL / CD11a) Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD.
A2611 Oleclumab (Anti-NT5E / CD73) Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.
A2871 Foralumab (Anti-CD3e) Foralumab (Anti-CD3e) is a monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon with immunomodulatory activity. MW: 145.56 KD.
A2618 Anti-Siglec-15 / CD33L3 (NC318) Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.
A2620 Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human IgG2 monoclonal antibody targeting the T-cell costimulatory receptor 4-1BB/CD137. It can be used for the research of relapsed/refractory follicular lymphoma (FL), non-Hodgkin lymphomas (NHL). MW :142.78.
A2161New Anti-mouse ICOSL (CD275)-InVivo Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily.
A2625 Anti-TNFSF13 / APRIL / CD256 (BION-1301) Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD.
A2626 Enoblituzumab (Anti-B7-H3 / CD276) Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
A2884 Giloralimab (Anti-TNFRSF5 / CD40) Giloralimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. MW: 145.26 KD.
S8908 AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73.
A2632 Samalizumab (Anti-CD200) Samalizumab (Anti-CD200) is a humanized monoclonal antibody that specifically targets CD200. It can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research. MW :144.84 KD.
A2634 Bleselumab (Anti-TNFRSF5 / CD40) Bleselumab (Anti-TNFRSF5 / CD40) is a human monoclonal antibody (mAb) targeting human CD40. It has the potential to prevents organ transplant rejection. MW :150 KD.
A2635 Sotigalimab (Anti-TNFRSF5 / CD40) Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD.
A2636 Dacetuzumab (Anti-TNFRSF5 / CD40) Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD.
A2039 Isatuximab (anti-CD38)

Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM.
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.
A2904 Anti-CD19 (Immunomedics hA19) Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD.
A2650 Anti-TNFRSF21 / DR6 / CD358 Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.
A2906 Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD.
A2914 Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD.
A2921 Lemzoparlimab (Anti-CD47) Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD.
A2922 Lilotomab (Anti-TSPAN26 / CD37) Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD.
E1276 MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
A2935 Mirzotamab (Anti-B7-H3 / CD276) Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
A2937 Anti-ICOS / CD278 (MEDI-570) Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD.
A2683 Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4) and OX40. It can be used in cancer immunology research. MW :146.36 KD.
A2501 Lumiliximab (Anti-FceR2 / CD23) Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD.
A2691 Anti-SIRPa / CD172a Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.
A2697 Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
A2512 Adecatumumab (Anti-EpCAM / TROP1 / CD326) Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD.
A2513 Anti-ENTPD1 / CD39 Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD.
A2514 Carotuximab (Anti-Endoglin / CD105) Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD.
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
A2707 Anti-MPL / TPOR / CD110 (TA136) Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD.
E1305 RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
A2969 Ocaratuzumab (Anti-CD20) Ocaratuzumab (anti-CD20) is a Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD.
A2971 Ofatumumab (Anti-CD20) Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.
A2167New Anti-mouse CD3-InVivo Anti-mouse CD3-InVivo reacts with mouse CD3, a transmembrane cell-surface protein that belongs to the immunoglobulin superfamily.CD3 is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes.
A2531 Anti-CSF2Rb / CD131 Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD.
A2532 Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD.
A2125 Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo.
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD.
A2986 Omburtamab (Anti-B7-H3 / CD276) Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD.
Int J Biol Sci, 2025, 21(1):306-327
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD.
A2992 Oportuzumab (Anti-EpCAM / TROP1 / CD326) Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD.
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.
A2993 Encelimab (Anti-LAG3 / CD223) Encelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD.
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD.
A2994 Favezelimab (Anti-LAG3 / CD223) Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD.
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD.
A2995 Fianlimab (Anti-LAG3 / CD223) Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
A4001New Tibulizumab (Anti-BAFF & IL-17) Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
A2034 Elotuzumab (anti-SLAMF7) Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
Nat Commun, 2024, 15(1):1367
J Cancer, 2024, 15(10):3065-3075
J Cancer, 2024, 15(10):3065-3075
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD.
A2996 Ieramilimab (Anti-LAG3 / CD223) Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD.
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD.
A2997 Miptenalimab (Anti-LAG3 / CD223) Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to an increased immune cell responses. MW :146.12 KD.
D4005 Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma.
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD.
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD.
A4008New Epcoritamab (Anti-CD20 & CD3) Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 KD.
A2560 Anti-CD28 Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD.
A2747 Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD.
A2561 Ocrelizumab (Anti-CD20) Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD.
A2748 Anti-SCFR / c-Kit / CD117 (CDX-0158) Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD.
A4010New Elranatamab-Bcmm (Anti-BCMA & CD3) Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.
A2563 Tafasitamab (Anti-CD19) Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD.
A2750 Anti-FcgR3a / CD16a (AFM13) Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. MW: 143.56 kD.
A2564 Inebilizumab (Anti-CD19) Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD.
A4014New Hx009 (Anti-CD47 & PD-1) Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.
A4015New Glofitamab (Anti-CD20 & CD3) Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.
A2754 Anti-TREM1 / CD354 (PY159) Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD.
A4016New TNB-383B (Anti-BCMA & BCMA & CD3) TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD.
A2312 Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa.
A2313 Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa.
A2314 Oxelumab (Anti-TNFSF4 / OX40L / CD252) Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa.
A4019New Linvoseltamab (Anti-BCMA & CD3) Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
A2758 Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD.
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.
A2759 Selicrelumab (Anti-TNFRSF5 / CD40) Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD.
A2136 Anti-mouse CD40-InVivo Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily.
A4022New Gefurulimab (Anti-C5 & Serum Albumin) Gefurulimab is a humanized bispecific VHH antibody targeting both terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory effects. It inhibits the terminal complement pathway by blocking the cleavage of C5 into C5a and C5b, reducing complement-mediated inflammation and cell lysis. By binding to albumin, gefurulimab increases its half-life, offering a potent and selective inhibition of terminal complement activity, including in the rare R885H C5 polymorphism. MW: 28.99 KD.
D4012 Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A2317 Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD.
A2760 Lintuzumab (Anti-Siglec-3 / CD33) Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD.
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A2762 Amlitelimab (Anti-TNFSF4 / OX40L / CD252) Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD.
A2140 Anti-mouse/human/rat CD47 (IAP)-InVivo Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells.
A4026New Talquetamab (Anti-CD3 & GPRC5D) Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.
D4016 Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
D4017 Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
A2321 Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD.
A4028New Mgd010 (Anti-CD79b & CD32b) Mgd010 is a bispecific dual-affinity retargeting (DART®) molecule that targets both the B cell surface proteins CD32B and CD79B, delivering a co-inhibitory signal to dampen B cell activation. It holds potential for treating autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. MW: 108.77 KD.
A2322 Brentuximab (Anti-TNFRSF8 / CD30) Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD.
A4029New Teclistamab (Anti-BCMA & CD3) Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.
A2323 Varlilumab (Anti-TNFRSF7 / CD27) Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
A4030New Alnuctamab (Anti-BCMA & CD3) Alnuctamab is a bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. It demonstrates encouraging antitumor activity in patients with relapsed or refractory multiple myeloma. MW: 192.35 KD.
A2324 Iscalimab (Anti-TNFRSF5 / CD40) Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD.
A2325 Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD.
A2768 Alomfilimab (Anti-ICOS / CD278) Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD.
A2326 Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD.
A4033New RO7122290 (Anti-4-1BB & FAP) RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.
A2327 Ragifilimab (Anti-TNFRSF18 / GITR / CD357) Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD.
A4034New Gen1042 (Anti-4-1BB & CD40) Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
A2328 Belantamab (Anti-TNFRSF17 / BCMA / CD269) Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD.
A4035New Hpn536 (Anti-CD3e & Mesothelin & Serum Albumin) Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid tumors. MW: 52.92 KD.
A2329 Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.
A4036New Gen3009 (Anti-CD37) Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.
A4037New Gen1044 (Anti-CD3 & TPBG) Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD.
A4038New Regn7075 (Anti-CD28 & EGFR) Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa.
D4034 Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab).
A2332 Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD.
A4040New Emb-06 (Anti-BCMA & CD3) Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa.
A2334 Tisotumab (Anti-Tissue factor / CD142) Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.
A4041New Ngm707 (Anti-LILRB2 & LILRB4) Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa.
A4042New Ibi-334 (Anti-B7-H3 & EGFR) Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa.
A2592 Praluzatamab (Anti-ALCAM / CD166) Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD.
D4039 Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A2338 Ontuxizumab (Anti-TEM1 / Endosialin / CD248) Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD
A4045New Odronextamab (Anti-CD20 & CD3) Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.
A4047New Gen1047 (Anti-B7-H4 & CD3) Gen1047 is a bispecific monoclonal antibody targeting CD3 on T cells and B7-H4. It induces T-cell-mediated cytotoxicity against B7-H4-positive cancer cells, making it a potential immunotherapy for malignant solid tumors with immunostimulating and antineoplastic activities. M.W 144.48 kDa.
A4048New Afm24 (Anti-EGFR & Fc-gamma-RIIIA) Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
A2342 Indatuximab (Anti-Syndecan-1 / CD138) Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD
A4049New Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa.
A4050New Imm0306 (Anti-CD20 & CD47) IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
D4045 Brentuximab vedotin Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.
A4057New Apv-527 (Anti-4-1BB & 5T4) APV-527 is a bispecific antibody targeting 4-1BB on T-cells and the 5T4 tumor antigen to stimulate immune responses against solid tumors. It is being developed for advanced solid tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, with positive safety and efficay. M.W 157.94 kDa
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD.
A2795 Denintuzumab (Anti-CD19) Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD.
A4059New Tebotelimab (Anti-LAG-3 & PD-1) Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa
D4051 Tisotumab vedotin Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A2354 Anti-SLAMF6 / CD352  Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD
A4062New Nivatrotamab (Anti-CD3 & GD2) Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa
A4063New Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa
A2357 Vadastuximab (Anti-Siglec-3 / CD33) Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD.
A2358 Inotuzumab (Anti-Siglec-2 / CD22) Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD.
A2361 Pepinemab (Anti-SEMA4D / CD100) Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD.
A2804 Coltuximab (Anti-CD19) Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD.
A2362 Anti-SCFR / c-Kit / CD117 Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD.
A2805 Ripertamab (Anti-CD20) Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD.
A4070New M701 (Anti-CD3 & EpCAM) M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa
A2806 Anti-CD20 (TRU-015) Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD.
A4071New Regn5678 (Anti-CD28 & PSMA) REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa
A2807 Ublituximab (Anti-CD20) Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity.  MW : 145.22 KD.
A4072New Flotetuzumab (Anti-CD3 & CD123) Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa
A2808 Veltuzumab (Anti-CD20) Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD.
A2809 Zuberitamab (Anti-CD20) Zuberitamab (Anti-CD20) is a human monoclonal antibody that targets CD20, with the potential to be used in research on diffuse large B-cell lymphoma. MW : 145.48 KD.
A2368 Roledumab (Anti-RHD / CD240d) Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD.
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
J Virol, 2020, 10.1128/JVI.00148-20
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Cell Rep Med, 2024, 5(2):101400
Cell Rep Med, 2023, S2666-3791(23)00310-5
Cell Rep Med, 2023, 4(9):101157
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Cancer Immunol Immunother, 2024, 73(6):108
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
J Extracell Vesicles, 2021, 10(5):e12078
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
S8908 AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73.
E1276 MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
E1305 RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
D4005 Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
D4012 Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
D4016 Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
D4017 Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
D4034 Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab).
D4039 Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
A2837 Anti-CD83 Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD.
A2027 Daratumumab (anti-CD38) Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.
Leuk Res, 2024, 147:107599
Brain Behav Immun Health, 2024, 42:100865
J Exp Med, 2022, 219(9)e20220214
A2029 Relatlimab (anti-LAG-3) Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells.
Mol Ther Nucleic Acids, 2024, 35(2):102225
Sci Rep, 2024, 14(1):31504
J Clin Invest, 2023, 133(9)e164528
A2372 Apamistamab (Anti-PTPRC / CD45) Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD.
A2815 Dalotuzumab (Anti-IGF1R / CD221) Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD.
A2373 Neihulizumab (Anti-PSGL1 / CD162) Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD.
A2816 Visilizumab (Anti-CD3) Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD.
A2817 Anti-CD34 Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD.
A2818 Felzartamab (Anti-CD38) Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD.
A2819 Mezagitamab (Anti-CD38) Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD.
A2820 Tregalizumab (Anti-CD4) Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD.
A2821 Anti-CD4 (TRX1) Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD.
A2823 Divozilimab (Anti-CD20) Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD.
A2824 Letaplimab (Anti-CD47) Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD.
A2825 Ligufalimab (Anti-CD47) Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD.
A2827 Urabrelimab (Anti-CD47) Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD.
A2830 Gatralimab (Anti-CD52) Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD.
A2388 Mupadolimab (Anti-NT5E / CD73) Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD.
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD.
A2168New Anti-human CD3 (UCHT1)-InVivo Anti-human CD3 (UCHT1)-InVivo reacts with human CD3ε a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily
A2390 Tesnatilimab (Anti-NKG2D / CD314) Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD.
A2143 Anti-mouse 4-1BB (CD137)-InVivo Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137.
A2834 Grisnilimab (Anti-CD7) Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD.
A2393 Lorvotuzumab (Anti-NCAM1 / CD56) Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD.
A2836 Iladatuzumab (Anti-CD79b) Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD.
A2147 Anti-mouse CXCR3 (CD183)-InVivo Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC).
A2395 Imaprelimab (Anti-MUC18 / MCAM / CD146) Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD.
A2838 Anti-CD9 Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD.
A2839 Anti-CDH1 / E-cadherin / CD324 Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD.
A2149 Anti-mouse CD19-InVivo Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily.
A2151 Anti-mouse IL-10R (CD210)-InVivo Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages.
A2402 Anti-Melanotransferrin / CD228 Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD.
A2154 Anti-mouse CD86 (B7-2)-InVivo Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member.
A2846 Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD.
A2852 Anti-CSF1R / M-CSFR / CD115 (LY3022855) Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD.
A2411 Polzastobart (Anti-LILRB2 / ILT4 / CD85d) Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities.
A2413 Mibavademab (Anti-LEPR / CD295) Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD.
A2414 Anti-LAMP1 / CD107a Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD.
A2159 Anti-mouse CSF1R (CD115)-InVivo Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family.
Cell Metab, 2024, S1550-4131(24)00415-7
A2127 Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro.
A2604 Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD.
A2130 Anti-mouse LFA-1α (CD11a)-InVivo Anti-mouse LFA-1α (CD11a)-InVivo(clone M17/4) is a monoclonal antibody reacts with mouse LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. It plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), and also functions in lymphocyte costimulatory signaling.
A2021 Tremelimumab (anti-CTLA-4) Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.
A2418 Lacutamab (Anti-KIR3DL2 / CD158k) Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD.
A2023 Obinutuzumab (anti-CD20) Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
A2133 Anti-mouse LAG-3-InVivo Anti-mouse LAG-3-InVivo (Clone: C9B7W) monoclonal antibody reacts with mouse LAG-3 also known as CD223. LAG-3 promotes immune responses by activating antigen-presenting cells. The C9B7W antibody has been reported to block the function of murine LAG-3 in vivo and in vitro.
A2421 Efalizumab (Anti-Integrin aL / ITGAL / CD11a) Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD.
A2611 Oleclumab (Anti-NT5E / CD73) Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.
A2871 Foralumab (Anti-CD3e) Foralumab (Anti-CD3e) is a monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon with immunomodulatory activity. MW: 145.56 KD.
A2618 Anti-Siglec-15 / CD33L3 (NC318) Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.
A2620 Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human IgG2 monoclonal antibody targeting the T-cell costimulatory receptor 4-1BB/CD137. It can be used for the research of relapsed/refractory follicular lymphoma (FL), non-Hodgkin lymphomas (NHL). MW :142.78.
A2161New Anti-mouse ICOSL (CD275)-InVivo Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily.
A2625 Anti-TNFSF13 / APRIL / CD256 (BION-1301) Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD.
A2626 Enoblituzumab (Anti-B7-H3 / CD276) Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
A2884 Giloralimab (Anti-TNFRSF5 / CD40) Giloralimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. MW: 145.26 KD.
A2632 Samalizumab (Anti-CD200) Samalizumab (Anti-CD200) is a humanized monoclonal antibody that specifically targets CD200. It can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research. MW :144.84 KD.
A2634 Bleselumab (Anti-TNFRSF5 / CD40) Bleselumab (Anti-TNFRSF5 / CD40) is a human monoclonal antibody (mAb) targeting human CD40. It has the potential to prevents organ transplant rejection. MW :150 KD.
A2635 Sotigalimab (Anti-TNFRSF5 / CD40) Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD.
A2636 Dacetuzumab (Anti-TNFRSF5 / CD40) Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD.
A2039 Isatuximab (anti-CD38)

Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM.
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.
A2904 Anti-CD19 (Immunomedics hA19) Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD.
A2650 Anti-TNFRSF21 / DR6 / CD358 Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.
A2906 Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD.
A2914 Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD.
A2921 Lemzoparlimab (Anti-CD47) Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD.
A2922 Lilotomab (Anti-TSPAN26 / CD37) Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD.
A2935 Mirzotamab (Anti-B7-H3 / CD276) Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
A2937 Anti-ICOS / CD278 (MEDI-570) Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD.
A2683 Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4) and OX40. It can be used in cancer immunology research. MW :146.36 KD.
A2501 Lumiliximab (Anti-FceR2 / CD23) Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD.
A2691 Anti-SIRPa / CD172a Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.
A2697 Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
A2512 Adecatumumab (Anti-EpCAM / TROP1 / CD326) Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD.
A2513 Anti-ENTPD1 / CD39 Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD.
A2514 Carotuximab (Anti-Endoglin / CD105) Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD.
A2707 Anti-MPL / TPOR / CD110 (TA136) Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD.
A2969 Ocaratuzumab (Anti-CD20) Ocaratuzumab (anti-CD20) is a Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD.
A2971 Ofatumumab (Anti-CD20) Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.
A2167New Anti-mouse CD3-InVivo Anti-mouse CD3-InVivo reacts with mouse CD3, a transmembrane cell-surface protein that belongs to the immunoglobulin superfamily.CD3 is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes.
A2531 Anti-CSF2Rb / CD131 Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD.
A2532 Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD.
A2125 Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo.
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD.
A2986 Omburtamab (Anti-B7-H3 / CD276) Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD.
Int J Biol Sci, 2025, 21(1):306-327
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD.
A2992 Oportuzumab (Anti-EpCAM / TROP1 / CD326) Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD.
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.
A2993 Encelimab (Anti-LAG3 / CD223) Encelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD.
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD.
A2994 Favezelimab (Anti-LAG3 / CD223) Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD.
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD.
A2995 Fianlimab (Anti-LAG3 / CD223) Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD.
A4001New Tibulizumab (Anti-BAFF & IL-17) Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
A2034 Elotuzumab (anti-SLAMF7) Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
Nat Commun, 2024, 15(1):1367
J Cancer, 2024, 15(10):3065-3075
J Cancer, 2024, 15(10):3065-3075
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD.
A2996 Ieramilimab (Anti-LAG3 / CD223) Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD.
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD.
A2997 Miptenalimab (Anti-LAG3 / CD223) Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to an increased immune cell responses. MW :146.12 KD.
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD.
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD.
A4008New Epcoritamab (Anti-CD20 & CD3) Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 KD.
A2560 Anti-CD28 Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD.
A2747 Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD.
A2561 Ocrelizumab (Anti-CD20) Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD.
A2748 Anti-SCFR / c-Kit / CD117 (CDX-0158) Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD.
A4010New Elranatamab-Bcmm (Anti-BCMA & CD3) Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.
A2563 Tafasitamab (Anti-CD19) Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD.
A2750 Anti-FcgR3a / CD16a (AFM13) Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. MW: 143.56 kD.
A2564 Inebilizumab (Anti-CD19) Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD.
A4014New Hx009 (Anti-CD47 & PD-1) Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.
A4015New Glofitamab (Anti-CD20 & CD3) Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.
A2754 Anti-TREM1 / CD354 (PY159) Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD.
A4016New TNB-383B (Anti-BCMA & BCMA & CD3) TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD.
A2312 Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa.
A2313 Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa.
A2314 Oxelumab (Anti-TNFSF4 / OX40L / CD252) Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa.
A4019New Linvoseltamab (Anti-BCMA & CD3) Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.
A2758 Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD.
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.
A2759 Selicrelumab (Anti-TNFRSF5 / CD40) Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD.
A2136 Anti-mouse CD40-InVivo Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily.
A4022New Gefurulimab (Anti-C5 & Serum Albumin) Gefurulimab is a humanized bispecific VHH antibody targeting both terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory effects. It inhibits the terminal complement pathway by blocking the cleavage of C5 into C5a and C5b, reducing complement-mediated inflammation and cell lysis. By binding to albumin, gefurulimab increases its half-life, offering a potent and selective inhibition of terminal complement activity, including in the rare R885H C5 polymorphism. MW: 28.99 KD.
A2317 Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD.
A2760 Lintuzumab (Anti-Siglec-3 / CD33) Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD.
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A2762 Amlitelimab (Anti-TNFSF4 / OX40L / CD252) Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD.
A2140 Anti-mouse/human/rat CD47 (IAP)-InVivo Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells.
A4026New Talquetamab (Anti-CD3 & GPRC5D) Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.
A2321 Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD.
A4028New Mgd010 (Anti-CD79b & CD32b) Mgd010 is a bispecific dual-affinity retargeting (DART®) molecule that targets both the B cell surface proteins CD32B and CD79B, delivering a co-inhibitory signal to dampen B cell activation. It holds potential for treating autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. MW: 108.77 KD.
A2322 Brentuximab (Anti-TNFRSF8 / CD30) Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD.
A4029New Teclistamab (Anti-BCMA & CD3) Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.
A2323 Varlilumab (Anti-TNFRSF7 / CD27) Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
A4030New Alnuctamab (Anti-BCMA & CD3) Alnuctamab is a bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. It demonstrates encouraging antitumor activity in patients with relapsed or refractory multiple myeloma. MW: 192.35 KD.
A2324 Iscalimab (Anti-TNFRSF5 / CD40) Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD.
A2325 Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD.
A2768 Alomfilimab (Anti-ICOS / CD278) Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD.
A2326 Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD.
A4033New RO7122290 (Anti-4-1BB & FAP) RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.
A2327 Ragifilimab (Anti-TNFRSF18 / GITR / CD357) Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD.
A4034New Gen1042 (Anti-4-1BB & CD40) Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.
A2328 Belantamab (Anti-TNFRSF17 / BCMA / CD269) Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD.
A4035New Hpn536 (Anti-CD3e & Mesothelin & Serum Albumin) Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid tumors. MW: 52.92 KD.
A2329 Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.
A4036New Gen3009 (Anti-CD37) Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.
A4037New Gen1044 (Anti-CD3 & TPBG) Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD.
A4038New Regn7075 (Anti-CD28 & EGFR) Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa.
A2332 Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD.
A4040New Emb-06 (Anti-BCMA & CD3) Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa.
A2334 Tisotumab (Anti-Tissue factor / CD142) Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.
A4041New Ngm707 (Anti-LILRB2 & LILRB4) Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa.
A4042New Ibi-334 (Anti-B7-H3 & EGFR) Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa.
A2592 Praluzatamab (Anti-ALCAM / CD166) Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A2338 Ontuxizumab (Anti-TEM1 / Endosialin / CD248) Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD
A4045New Odronextamab (Anti-CD20 & CD3) Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.
A4047New Gen1047 (Anti-B7-H4 & CD3) Gen1047 is a bispecific monoclonal antibody targeting CD3 on T cells and B7-H4. It induces T-cell-mediated cytotoxicity against B7-H4-positive cancer cells, making it a potential immunotherapy for malignant solid tumors with immunostimulating and antineoplastic activities. M.W 144.48 kDa.
A4048New Afm24 (Anti-EGFR & Fc-gamma-RIIIA) Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
A2342 Indatuximab (Anti-Syndecan-1 / CD138) Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD
A4049New Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa.
A4050New Imm0306 (Anti-CD20 & CD47) IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.
A4057New Apv-527 (Anti-4-1BB & 5T4) APV-527 is a bispecific antibody targeting 4-1BB on T-cells and the 5T4 tumor antigen to stimulate immune responses against solid tumors. It is being developed for advanced solid tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, with positive safety and efficay. M.W 157.94 kDa
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD.
A2795 Denintuzumab (Anti-CD19) Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD.
A4059New Tebotelimab (Anti-LAG-3 & PD-1) Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A2354 Anti-SLAMF6 / CD352  Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD
A4062New Nivatrotamab (Anti-CD3 & GD2) Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa
A4063New Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa
A2357 Vadastuximab (Anti-Siglec-3 / CD33) Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD.
A2358 Inotuzumab (Anti-Siglec-2 / CD22) Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD.
A2361 Pepinemab (Anti-SEMA4D / CD100) Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD.
A2804 Coltuximab (Anti-CD19) Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD.
A2362 Anti-SCFR / c-Kit / CD117 Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD.
A2805 Ripertamab (Anti-CD20) Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD.
A4070New M701 (Anti-CD3 & EpCAM) M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa
A2806 Anti-CD20 (TRU-015) Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD.
A4071New Regn5678 (Anti-CD28 & PSMA) REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa
A2807 Ublituximab (Anti-CD20) Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity.  MW : 145.22 KD.
A4072New Flotetuzumab (Anti-CD3 & CD123) Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa
A2808 Veltuzumab (Anti-CD20) Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD.
A2809 Zuberitamab (Anti-CD20) Zuberitamab (Anti-CD20) is a human monoclonal antibody that targets CD20, with the potential to be used in research on diffuse large B-cell lymphoma. MW : 145.48 KD.
A2368 Roledumab (Anti-RHD / CD240d) Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD.
S6239 PMX-53 PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
Thromb J, 2022, 20(1):24
S0474 Avacopan Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.
Nat Commun, 2024, 15(1):6519
Cell Death Dis, 2022, 13(5):500
P1208New PMX 205 acetate

PMX 205 acetate is a cyclic hexapeptide that acts as a potent C5a receptor (C5aR, CD88) antagonist with an IC50 of 31 nM.
Ecotoxicol Environ Saf, 2025, 289:117627
Int Immunopharmacol, 2023, 125(Pt B):111112
S0525 ADH-503 (GB1275) ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
A2168New Anti-human CD3 (UCHT1)-InVivo Anti-human CD3 (UCHT1)-InVivo reacts with human CD3ε a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily
P1208New PMX 205 acetate

PMX 205 acetate is a cyclic hexapeptide that acts as a potent C5a receptor (C5aR, CD88) antagonist with an IC50 of 31 nM.
Ecotoxicol Environ Saf, 2025, 289:117627
Int Immunopharmacol, 2023, 125(Pt B):111112
A2161New Anti-mouse ICOSL (CD275)-InVivo Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily.
A2167New Anti-mouse CD3-InVivo Anti-mouse CD3-InVivo reacts with mouse CD3, a transmembrane cell-surface protein that belongs to the immunoglobulin superfamily.CD3 is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes.
A4001New Tibulizumab (Anti-BAFF & IL-17) Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.
A4008New Epcoritamab (Anti-CD20 & CD3) Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 KD.
A4010New Elranatamab-Bcmm (Anti-BCMA & CD3) Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.
A4014New Hx009 (Anti-CD47 & PD-1) Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.
A4015New Glofitamab (Anti-CD20 & CD3) Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.
A4016New TNB-383B (Anti-BCMA & BCMA & CD3) TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD.
A4019New Linvoseltamab (Anti-BCMA & CD3) Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.
A4022New Gefurulimab (Anti-C5 & Serum Albumin) Gefurulimab is a humanized bispecific VHH antibody targeting both terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory effects. It inhibits the terminal complement pathway by blocking the cleavage of C5 into C5a and C5b, reducing complement-mediated inflammation and cell lysis. By binding to albumin, gefurulimab increases its half-life, offering a potent and selective inhibition of terminal complement activity, including in the rare R885H C5 polymorphism. MW: 28.99 KD.
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A4026New Talquetamab (Anti-CD3 & GPRC5D) Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.
A4028New Mgd010 (Anti-CD79b & CD32b) Mgd010 is a bispecific dual-affinity retargeting (DART®) molecule that targets both the B cell surface proteins CD32B and CD79B, delivering a co-inhibitory signal to dampen B cell activation. It holds potential for treating autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. MW: 108.77 KD.
A4029New Teclistamab (Anti-BCMA & CD3) Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.
A4030New Alnuctamab (Anti-BCMA & CD3) Alnuctamab is a bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. It demonstrates encouraging antitumor activity in patients with relapsed or refractory multiple myeloma. MW: 192.35 KD.
A4033New RO7122290 (Anti-4-1BB & FAP) RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.
A4034New Gen1042 (Anti-4-1BB & CD40) Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.
A4035New Hpn536 (Anti-CD3e & Mesothelin & Serum Albumin) Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid tumors. MW: 52.92 KD.
A4036New Gen3009 (Anti-CD37) Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.
A4037New Gen1044 (Anti-CD3 & TPBG) Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.
A4038New Regn7075 (Anti-CD28 & EGFR) Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa.
A4040New Emb-06 (Anti-BCMA & CD3) Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa.
A4041New Ngm707 (Anti-LILRB2 & LILRB4) Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa.
A4042New Ibi-334 (Anti-B7-H3 & EGFR) Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A4045New Odronextamab (Anti-CD20 & CD3) Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.
A4047New Gen1047 (Anti-B7-H4 & CD3) Gen1047 is a bispecific monoclonal antibody targeting CD3 on T cells and B7-H4. It induces T-cell-mediated cytotoxicity against B7-H4-positive cancer cells, making it a potential immunotherapy for malignant solid tumors with immunostimulating and antineoplastic activities. M.W 144.48 kDa.
A4048New Afm24 (Anti-EGFR & Fc-gamma-RIIIA) Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.
A4049New Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa.
A4050New Imm0306 (Anti-CD20 & CD47) IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A4057New Apv-527 (Anti-4-1BB & 5T4) APV-527 is a bispecific antibody targeting 4-1BB on T-cells and the 5T4 tumor antigen to stimulate immune responses against solid tumors. It is being developed for advanced solid tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, with positive safety and efficay. M.W 157.94 kDa
A4059New Tebotelimab (Anti-LAG-3 & PD-1) Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A4062New Nivatrotamab (Anti-CD3 & GD2) Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa
A4063New Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa
A4070New M701 (Anti-CD3 & EpCAM) M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa
A4071New Regn5678 (Anti-CD28 & PSMA) REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa
A4072New Flotetuzumab (Anti-CD3 & CD123) Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa

Choose Selective CD markers Inhibitors

Tags: CD markers inhibitor|CD markers agonist|CD markers activator|CD markers inducer|CD markers antagonist|CD markers signaling pathway|CD markers assay kit